Huahai Pharmaceutical's Subsidiary Receives FDA Approval to Initiate Phase I Clinical Trial of HB0043 Injection in the U.S.

Log in to Sina Finance APP, search for 【Information Disclosure】to view more evaluation levels.

Gelonghui September 17 |Huahai Pharmaceutical(600521.SH) Announced that its subsidiary, Shanghai Huaota Biopharmaceutical Co., Ltd.Huaota BiopharmaceuticalShanghai Huaota Biopharmaceutical Co., Ltd. has received approval from the U.S. FDA to conduct a Phase I clinical trial in the United States for the injectable drug HB0043. This drug is a recombinant humanized IgG1-type bispecific antibody used for treating autoimmune diseases such as hidradenitis suppurativa. To date, the company has invested approximately RMB 71.11 million in research and development for this project. The pharmaceutical product development cycle is long and involves various uncertainties, and the competitive landscape for future products may change. The company will monitor the drug's research progress and fulfill its information disclosure obligations.